Johnson & Johnson Submits FDA Application for Multiple Myeloma Drug

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen announced on Monday that it had filed a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for its multiple myeloma drug Darzalex (also known as daratumumab).